&lt;p&gt;Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway&lt;/p&gt;

Wang, Yanjun; Pang, Bo; Zhang, Rui; Fu, Yan; Pang, Qi

doi:10.2147/dddt.s218371

Cited by 8 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, sensitization of cancer cells to chemo-or radiotherapy is largely attributed to enhanced apoptosis of cancerous cells. 44 However, ROS generation can also contribute to tissue damage. This was most recently described in the case of COVID-19, where overabundant ROS promoted sudden patient decline.…”

Section: Discussionmentioning

confidence: 99%

Bestatin as a treatment modality in experimental periodontitis

Kamińska

Benedyk-Machaczka

Adamowicz

et al. 2023

Journal of Periodontology

View full text Add to dashboard Cite

BackgroundChronic periodontitis (CP), the most prevalent dysbiotic bacteria‐driven chronic inflammatory disease, is an underestimated global health problem in itself, and due to a causative relationship with other disorders such as cardiovascular diseases or Alzheimer disease. The CP pathogenesis is primarily driven by Porphyromonas gingivalis in humans, and Porphyromonas gulae in dogs. These microorganisms initiate a pathogenic shift in the composition of the tooth‐surface microflora. Our objective was to evaluate antimicrobial effects of bestatin, a potential CP drug candidate.MethodsWe evaluated bestatin bacteriostatic efficiency against periodontopathogens in planktonic cultures via microplate assay, and mono‐ and multispecies oral biofilm models. Neutrophil bactericidal activities, such as phagocytosis, were investigated in vitro using granulocytes isolated from the peripheral blood. The therapeutic efficacy and the immunomodulatory function of bestatin was assessed in a murine model of CP.ResultsBestatin exhibited bacteriostatic activity against both P. gingivalis and P. gulae, and controlled the formation and species composition of the biofilm. We demonstrated that bestatin promotes the phagocytosis of periodontopathogens by neutrophils. Finally, we found that providing bestatin in the animal feed prevented alveolar bone resorption.ConclusionsWe show that in a murine model of CP bestatin not only shifted the biofilm species composition from pathogenic to a commensal one, but also promoted bacteria clearance by immune cells and alleviated inflammation. Taken together, these results suggest that bestatin is a promising drug choice for the treatment and/or prevention of periodontitis and clinical trials are required to fully evaluate its potency.

show abstract

Section: Discussionmentioning

confidence: 99%

Bestatin as a treatment modality in experimental periodontitis

Kamińska

Benedyk-Machaczka

Adamowicz

et al. 2023

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…Additionally, ubenimex can also induce the death and apoptosis of autophagocytes, which indicates that a mixed type of programmed cell death occurs in bladder tumor cells after ubenimex application. 26 Toshiyama et al 27 Found that ubenimex and fluorouracil, cisplatin or adriamycin had a synergistic effect and played an effective anti-tumor role, without increase in adverse drug reactions. Moreover, ubenimex is also an inhibitor of CD13, which can be used as an immune adjuvant to improve the immune status of the body.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor

Shao¹,

Wang²,

Wang

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To evaluate the clinical value of intravesical gemcitabine combined with immunotherapy in patients with non-muscle-invasive bladder carcinoma (NMIBC) after transurethral resection of bladder tumor (TURBT). Methods: Eighty patients with non-muscle-invasive urothelial carcinoma treated in Baoding No.1 Hospital from November 2016 to November 2019 were randomly divided into two groups, with 40 patients in each group. Both groups underwent TURBT. After surgery, the research group was treated with intravesical chemotherapy using gemcitabine combined with ubenimex, while the control group was given 40 mg pirarubicin by intravesical instillation. Postoperative condition was evaluated by cystoscopy every three months in both groups. The recurrence six months, one year and two years after treatment, the incidence of lower urinary tract symptoms such as dysuria, hematuria and frequent urination, general adverse drug reactions such as rashes, liver function damage and gastrointestinal reaction, as well as the changes in CD3+, CD4+, CD8+ and CD4+/CD8+ T lymphocyte subsets before and after treatment were comparatively analyzed between the two groups. Results: The recurrence rate showed no statistical significance between the two groups 6 months after treatment (p=0.17), but significant differences one year (p=0.04) and two years (p=0.03) after treatment, which were significantly lower in the research group than the control group. The incidence of adverse drug reactions was 22.5% in the research group and 7.5% in the control group, without significant difference (p=0.36). The incidence of lower urinary tract symptoms was 32.5% and 55%, respectively, in the research group and the control group. The incidence of lower urinary tract symptoms in the research group was significantly lower compared with the control group, with a statistically significant difference (p=0.04). After treatment, CD3+, CD4+ and CD4+/CD8+ levels in the research group increased significantly than those in the control group, with statistically significant differences (CD3+, p=0.01; CD4+, p=0.00; CD4+/CD8+, p=0.00). Conclusions: For NMIBC patients receiving bladder-preserving surgery, intravesical gemcitabine combined with immunotherapy can reduce the recurrence rate, relieve lower urinary tract symptoms, increase the tolerance of patients to intravesical chemotherapy and significantly improve the function of T lymphocytes, without obvious increase in adverse drug reactions. Therefore, it is safe and effective, and has certain clinical value. doi: https://doi.org/10.12669/pjms.38.5.4599 How to cite this:Shao L, Wang H, Wang J, Yuan X, Sha Q. Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor. Pak J Med Sci. 2022;38(5):---------. doi: https://doi.org/10.12669/pjms.38.5.4599 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Moreover, an inhibitor of APN, ubenimex, was reported to induce apoptotic cell death in rat pituitary tumour cells by promoting ROS generation. 52 Therefore, several uorescent probes for imaging of tumour tissues and drug screening through the targeting of APN have been created. 53,54 Li et al 55 reported three ratiometric uorescent probes 9-11 for detecting the activities of APN (Fig.…”

Section: Cancermentioning

confidence: 99%